Enhancing bioanalysis efficiency via automated processes
In this presentation, we will explore case studies involving ADA, NAbs, PK and biomarker assays, showcasing the successful application of the KingFisherTM in automating bead processing steps.
The evolution of bioanalytical assays from the use of manual pipetting to semi and fully automated processes has been slow to be implemented, particularly in the context of complex assays. Reluctance to adopt these advanced technologies, especially for multifaceted assays like biotin-drug extraction with acid dissociation (BEAD) in ADA and NAbs, can lead to suboptimal performance, imprecision and decreased sensitivity—falling short of regulatory standards. This presentation explores case studies demonstrating the successful use of the KingFisher in enhancing ADA, Nabs, PK and biomarker assays. Additionally, it offers guidance on implementing similar improvements in other laboratories.
What will you learn?
- Advantages of BEAD extraction procedure
- The use of KingFisher in a CRO environment
- Guidance on implementing automated processes
Who this may interest?
- Pharmaceutical companies
- CRO
- Biotech companies
Speaker
Dr Issa Jyamubandi
Principal Scientist
Resolian (Cambridge, UK)
Issa holds a Bachelor of Science degree in Biomedical Sciences from the University of Coventry (Coventry, UK) and completed his PhD at the University of East Anglia (Norwich, UK). His doctoral research was dedicated to advancing peptide drug conjugate therapies with a specific focus on targeted treatment for melanoma. With a career spanning more than 13 years in the bioanalytical sector, Issa has specialized in developing and validating assays for anti-drug antibodies (ADA), neutralizing antibodies (Nabs), pharmacokinetics (PK) and biomarkers. His expertise spans a diverse array of platforms, including MSD, Gyrolab and various absorbance, fluorescence and luminescence technologies.
Currently serving as a Principal Scientist, Issa plays a crucial role in supporting a broad spectrum of therapeutic programs. These programs encompass a wide range of modalities, ranging from small peptides (<5kDa) to larger compounds, including antibody–drug conjugates (ADCs), enzymes, pegylated therapies, oligonucleotide-based treatments, AAV gene therapy and transgene products. His contributions extend from the early preclinical stages of development to active involvement in clinical trials, showcasing his comprehensive and impactful role in advancing therapeutic initiatives.
This webinar was recorded on Tuesday 15 February 2024